Medacta is on pace to generate more than $800 million in orthopedic sales in 2025. Despite its size, the company is also one of the fastest growing companies in the space, with a CAGR of 14% from 2017 to 2025’s estimated finish.
Our chart of the month shows Medacta’s sales trajectory by segment by year. The company’s anterior approach for hips and kinematic alignment have worked synergistically, especially in the U.S., as service levels incentivize surgeons to switch both their knee and hip implants to Medacta.
The company’s technology ecosystem, including NextAR and MySpine, set it apart from other mid-tier competitors and have driven shoulder and spine revenue growth at multiples of the market average.
However, it is Medacta’s sports medicine business that could be the next be growth driver. Its acquisition of Parcus Medical and demonstrated history of rapid innovation position Medacta well to be a disruptive force in sports medicine.
Growing its sports medicine footprint will help Medacta penetrate U.S. ASCs more rapidly, which will have a pull-through effect on its joint replacement business.
Additionally, surgeons in Europe tend to span both sports medicine and joint replacement segments, giving the company further cross-selling opportunities.
Medacta Sales by Segment
Medacta is on pace to generate more than $800 million in orthopedic sales in 2025. Despite its size, the company is also one of the fastest growing companies in the space, with a CAGR of 14% from 2017 to 2025's estimated finish.
Our chart of the month shows Medacta's sales trajectory by segment by year. The...
Medacta Sales by Segment
Medacta is on pace to generate more than $800 million in orthopedic sales in 2025. Despite its size, the company is also one of the fastest growing companies in the space, with a CAGR of 14% from 2017 to 2025’s estimated finish.
Our chart of the month shows Medacta’s sales trajectory by segment by year. The company’s anterior approach for hips and kinematic alignment have worked synergistically, especially in the U.S., as service levels incentivize surgeons to switch both their knee and hip implants to Medacta.
The company’s technology ecosystem, including NextAR and MySpine, set it apart from other mid-tier competitors and have driven shoulder and spine revenue growth at multiples of the market average.
However, it is Medacta’s sports medicine business that could be the next be growth driver. Its acquisition of Parcus Medical and demonstrated history of rapid innovation position Medacta well to be a disruptive force in sports medicine.
Growing its sports medicine footprint will help Medacta penetrate U.S. ASCs more rapidly, which will have a pull-through effect on its joint replacement business.
Additionally, surgeons in Europe tend to span both sports medicine and joint replacement segments, giving the company further cross-selling opportunities.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
